Perspective Therapeutics (CATX) News Today $3.43 +0.27 (+8.54%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and eight have given a bJanuary 19 at 2:51 AM | marketbeat.comPerspective Therapeutics (CATX) Gets a Hold from Bank of America SecuritiesJanuary 16, 2025 | markets.businessinsider.comPerspective Therapeutics (NYSE:CATX) Earns Outperform Rating from Royal Bank of CanadaJanuary 16, 2025 | americanbankingnews.comPerspective Therapeutics’ Strategic Advancements and Positive Clinical Developments Justify Buy RatingJanuary 15, 2025 | markets.businessinsider.comPerspective Therapeutics (NYSE:CATX) Earns "Outperform" Rating from WedbushJanuary 15, 2025 | americanbankingnews.comPerspective Therapeutics (CATX) Receives a Buy from Truist FinancialJanuary 14, 2025 | markets.businessinsider.comRoyal Bank of Canada Reiterates Outperform Rating for Perspective Therapeutics (NYSE:CATX)Royal Bank of Canada reaffirmed an "outperform" rating and set a $16.00 target price on shares of Perspective Therapeutics in a research report on Tuesday.January 14, 2025 | marketbeat.comPerspective Therapeutics (NYSE:CATX) Receives "Outperform" Rating from WedbushWedbush restated an "outperform" rating and set a $11.00 price target on shares of Perspective Therapeutics in a research report on Monday.January 13, 2025 | marketbeat.comPerspective Therapeutics provides business updates, strategic prioritiesJanuary 13, 2025 | markets.businessinsider.comPerspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 13, 2025 | stockhouse.comPerspective Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 10, 2025 | markets.businessinsider.comPerspective Therapeutics, Inc.: Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial OfficerJanuary 6, 2025 | finanznachrichten.dePerspective Therapeutics Appoints Juan Graham As CFOJanuary 6, 2025 | markets.businessinsider.comPerspective Therapeutics Appoints Juan Graham, MBA as Chief Financial OfficerJanuary 6, 2025 | globenewswire.comPerspective Therapeutics, Inc. (NYSE:CATX) Receives Average Recommendation of "Moderate Buy" from BrokeragesPerspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the nine analysts that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating and eight have given a buy rating toDecember 25, 2024 | marketbeat.comBullish On Perspective Therapeutics: Early Successes And Large Oncology TAMDecember 23, 2024 | seekingalpha.comState Street Corp Grows Position in Perspective Therapeutics, Inc. (NYSE:CATX)State Street Corp boosted its position in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 119.6% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,190,239 shares of the company's stock aftDecember 22, 2024 | marketbeat.comPerspective Therapeutics: Definitely Not Looking Overvalued NowDecember 20, 2024 | seekingalpha.comCharles Schwab Investment Management Inc. Acquires 298,778 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)Charles Schwab Investment Management Inc. grew its holdings in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 221.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 433,522 shares of the companDecember 13, 2024 | marketbeat.comWalleye Capital LLC Sells 494,706 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)Walleye Capital LLC cut its position in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 96.5% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 18,117 shares of the company's stock after selling 494,706 shares during the qDecember 11, 2024 | marketbeat.comPerspective Therapeutics management to meet with TruistDecember 10, 2024 | markets.businessinsider.comInsider Buying: Perspective Therapeutics, Inc. (NYSE:CATX) Director Purchases 25,975 Shares of StockDecember 7, 2024 | insidertrades.comPerspective Therapeutics, Inc. (NYSE:CATX) Director Acquires $100,003.75 in StockPerspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) Director Heidi Henson purchased 25,975 shares of the firm's stock in a transaction that occurred on Wednesday, December 4th. The stock was bought at an average cost of $3.85 per share, for a total transaction of $100,003.75. Following the purchase, the director now owns 25,975 shares in the company, valued at $100,003.75. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.December 6, 2024 | marketbeat.comJanus Henderson Group PLC Boosts Holdings in Perspective Therapeutics, Inc. (NYSE:CATX)Janus Henderson Group PLC grew its position in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 8.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,799,352 shares of the company's stock after purchDecember 6, 2024 | marketbeat.comFmr LLC Has $73.49 Million Stake in Perspective Therapeutics, Inc. (NYSE:CATX)Fmr LLC raised its holdings in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 3,994.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,504,822 shares of the company's stock after buying an additional 5,370,392 shDecember 6, 2024 | marketbeat.comPerspective Therapeutics, Inc. (NYSE:CATX) CEO Johan M. Spoor Acquires 8,000 SharesDecember 5, 2024 | insidertrades.comPerspective Therapeutics, Inc. (NYSE:CATX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and eightNovember 30, 2024 | marketbeat.comRobert F. Williamson III Buys 6,266 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) StockNovember 28, 2024 | insidertrades.comPerspective Therapeutics, Inc. (NYSE:CATX) CFO Jonathan Robert Hunt Acquires 12,829 SharesPerspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) CFO Jonathan Robert Hunt purchased 12,829 shares of the stock in a transaction on Monday, November 25th. The shares were acquired at an average cost of $3.82 per share, for a total transaction of $49,006.78. Following the transaction, the chief financial officer now owns 48,800 shares of the company's stock, valued at approximately $186,416. The trade was a 35.66 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.November 27, 2024 | marketbeat.comPerspective Therapeutics, Inc. to Present at Upcoming Investor Conferences in New York and FloridaNovember 27, 2024 | quiverquant.comPerspective Therapeutics to Participate in Upcoming Investor Conferences in DecemberNovember 27, 2024 | globenewswire.comInsider Buying: Perspective Therapeutics, Inc. (NYSE:CATX) CEO Buys 14,500 Shares of StockNovember 27, 2024 | insidertrades.comJohan M. Spoor Purchases 14,500 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) StockPerspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) CEO Johan M. Spoor bought 14,500 shares of Perspective Therapeutics stock in a transaction dated Monday, November 25th. The shares were acquired at an average price of $3.78 per share, with a total value of $54,810.00. Following the completion of the purchase, the chief executive officer now directly owns 152,072 shares in the company, valued at $574,832.16. This trade represents a 10.54 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.November 26, 2024 | marketbeat.comPerspective Therapeutics downgraded to Neutral from Buy at BofANovember 26, 2024 | markets.businessinsider.comCautious Hold Rating for Perspective Therapeutics Amid Efficacy and Safety ConcernsNovember 26, 2024 | markets.businessinsider.comB of A Securities Downgrades Perspective Therapeutics (CATX)November 26, 2024 | msn.comBank of America Downgrades Perspective Therapeutics (NYSE:CATX) to NeutralBank of America downgraded shares of Perspective Therapeutics from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $24.00 to $5.00 in a research report on Monday.November 25, 2024 | marketbeat.comPerspective Therapeutics selloff a buying opportunity, says JonesResearchNovember 23, 2024 | msn.comTruist Financial Releases a Buy Rating on Perspective Therapeutics (CATX)November 22, 2024 | markets.businessinsider.comPerspective Therapeutics price target lowered to $16 from $22 at OppenheimerNovember 22, 2024 | markets.businessinsider.comPerspective Therapeutics (NYSE:CATX) Given New $16.00 Price Target at OppenheimerOppenheimer lowered their target price on shares of Perspective Therapeutics from $22.00 to $16.00 and set an "outperform" rating for the company in a report on Friday.November 22, 2024 | marketbeat.comPerspective Therapeutics to pursue dose escalation in Phase 1/2a clinical trialNovember 22, 2024 | markets.businessinsider.comPerspective slips after Phase 1/2 trial data for radio pharma drugNovember 22, 2024 | msn.comPerspective Therapeutics, Inc. Reports Positive Initial Results from Phase 1/2a Trial of [212Pb]VMT-α-NET for Neuroendocrine TumorsNovember 21, 2024 | quiverquant.comPerspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical SymposiumNovember 21, 2024 | globenewswire.comPerspective Therapeutics (CATX) Receives a Buy from RBC CapitalNovember 20, 2024 | markets.businessinsider.comCATX FY2024 EPS Estimate Boosted by Cantor FitzgeraldPerspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Stock analysts at Cantor Fitzgerald upped their FY2024 earnings per share estimates for shares of Perspective Therapeutics in a note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now expects that the cNovember 18, 2024 | marketbeat.comPerspective Therapeutics, Inc. to Present Initial Results of [212Pb]VMT-α-NET Phase 1/2a Trial at NANETS SymposiumNovember 15, 2024 | quiverquant.comPerspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024November 15, 2024 | globenewswire.comOptimistic Outlook for Perspective Therapeutics Amid Promising Trial DevelopmentsNovember 14, 2024 | markets.businessinsider.com Get Perspective Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter. Email Address CATX Media Mentions By Week CATX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CATX News Sentiment▼0.280.48▲Average Medical News Sentiment CATX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CATX Articles This Week▼84▲CATX Articles Average Week Get Perspective Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies FNA News EYE News AXGN News BVS News AVNS News CBLL News IRMD News BFLY News SIBN News KIDS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:CATX) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CATX Stock Alerts